Anne Favel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anne Favel has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Alexandre Gauthier
Service de Reanimation Polyvalente, CHU Réunion, St Pierre, France
1 shared publication- Carole Berruyer
Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, 13288 Marseille, France
1 shared publication - Christophe Bordi
LISM, IMM, Aix-Marseille Univ and CNRS, 13402 Marseille, France
1 shared publication David Redelberger
Centre National de la Recherche Scientifique, Laboratoire d' Ingenierie des Systemes Macromoleculaires, Institut de Microbiologie de la Mediterranee, Aix Marseille Université, 13402 Marseille, France
1 shared publicationDea Garcia‐Hermoso
Institut Pasteur, CNRS URA3012, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France
1 shared publication- Gautier Hoarau
Service d’Ophtalmologie, Hôpital Bicêtre, CRMR OPHTARA, Université Paris-Saclay, Le Kremlin Bicêtre, France
1 shared publication
Latest Publications
Trametes polyzona, an emerging filamentous basidiomycete in Réunion Island
Summary: We describe two serious Trametes polyzona pulmonary infections, which occurred in Réunion Island, in critically ill patients. The identification was performed using sequencing of the internal transcribed spacer region of ribosomal DNA and D1/D2 region of 28S rDNA. In one case, the significance of T. polyzona in the pathological process was certain, proven by histopathological evidence of fungal lung infection. T. polyzona, an emerging filamentous basidiomycete, prevalent in tropical areas, has not been described so far in human infections.
Trametes polyzona, an emerging filamentous basidiomycete in Réunion Island
Summary: We describe two serious Trametes polyzona pulmonary infections, which occurred in Réunion Island, in critically ill patients. The identification was performed using sequencing of the internal transcribed spacer region of ribosomal DNA and D1/D2 region of 28S rDNA. In one case, the significance of T. polyzona in the pathological process was certain, proven by histopathological evidence of fungal lung infection. T. polyzona, an emerging filamentous basidiomycete, prevalent in tropical areas, has not been described so far in human infections.
- Open Access
- 10 October 2016
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 213 (11) , 2269-2279
M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation
Myeloablative treatment preceding hematopoietic stem cell (HSC) and progenitor cell (HS/PC) transplantation results in severe myeloid cytopenia and susceptibility to infections in the lag period before hematopoietic recovery. We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instructed myeloid commitment in HSCs. In this study, we tested whether this effect had therapeutic benefit in improving protection against pathogens after HS/PC transplantation. M-CSF treatment resulted in an increased production of mature myeloid donor cells and an increased survival of recipient mice infected with lethal doses of clinically relevant opportunistic pathogens, namely the bacteria Pseudomonas aeruginosa and the fungus Aspergillus fumigatus. M-CSF treatment during engraftment or after infection efficiently protected from these pathogens as early as 3 days after transplantation and was effective as a single dose. It was more efficient than granulocyte CSF (G-CSF), a common treatment of severe neutropenia, which showed no protective effect under the tested conditions. M-CSF treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-CSF, did not impede recovery of HS/PCs, thrombocyte numbers, or glucose metabolism. These results encourage potential clinical applications of M-CSF to prevent severe infections after HS/PC transplantation.
- 10 October 2016
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 213 (11) , 2269-2279
Open AccessM-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation
Myeloablative treatment preceding hematopoietic stem cell (HSC) and progenitor cell (HS/PC) transplantation results in severe myeloid cytopenia and susceptibility to infections in the lag period before hematopoietic recovery. We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instructed myeloid commitment in HSCs. In this study, we tested whether this effect had therapeutic benefit in improving protection against pathogens after HS/PC transplantation. M-CSF treatment resulted in an increased production of mature myeloid donor cells and an increased survival of recipient mice infected with lethal doses of clinically relevant opportunistic pathogens, namely the bacteria Pseudomonas aeruginosa and the fungus Aspergillus fumigatus. M-CSF treatment during engraftment or after infection efficiently protected from these pathogens as early as 3 days after transplantation and was effective as a single dose. It was more efficient than granulocyte CSF (G-CSF), a common treatment of severe neutropenia, which showed no protective effect under the tested conditions. M-CSF treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-CSF, did not impede recovery of HS/PCs, thrombocyte numbers, or glucose metabolism. These results encourage potential clinical applications of M-CSF to prevent severe infections after HS/PC transplantation.